Perspective: repurposed Drugs for COVID-19

Na‐Bangchang, Kesara; Porasuphatana, Supattra; Karbwang, Juntra

doi:10.5114/aoms/152467

Cited by 7 publications

(2 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Furthermore, research on off-label use of herbal medicine such as andrographolide or repurposed drugs like hydroxychloroquine or ivermectin was common during the pandemic. 27,28 In this survey, many REC Members agreed that the use of herbal medicine and off-label drugs should undergo clinical trials subject to REC review to gather evidence on their safety and efficacy for COVID-19. It was acknowledged that the dose and usage of these substances may differ from their established indications, which could lead to adverse side effects.…”

Section: The Ability Of Recs To Identify General Ethical Issues Invol...mentioning

confidence: 99%

The readiness of the Asian research ethics committees in responding to the COVID-19 pandemic: A multi-country survey

Karbwang,

Torres,

Navarro

et al. 2024

F1000Res

Self Cite

View full text Add to dashboard Cite

Background COVID-19 is a highly challenging infectious disease. Research ethics committees (RECs) have challenges reviewing research on this new pandemic disease under a tight timeline and public pressure. This study aimed to assess RECs’ responses and review during the outbreak in seven Asian countries where the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER) networks are active. Methods The online survey was conducted in seven Asian countries from April to August 2021. Two sets of online questionnaires were developed, one set for the chairs/secretaries and another set for the REC members. The REC profiles obtained from the REC members are descriptive in nature. Data from the chairs/secretaries were compared between the RECs with external quality assessment (SIDCER-Recognized RECs, SR-RECs) and non-external quality assessment (Non-SIDCER-Recognized RECs, NSR-RECs) and analyzed using a Chi-squared test. Results A total of 688 REC members and 197 REC chairs/secretaries participated in the survey. Most RECs have standard operating procedures (SOPs), and have experience in reviewing all types of protocols, but 18.1% had no experience reviewing COVID-19 protocols. Most REC members need specific training on reviewing COVID-19 protocols (93%). In response to the outbreak, RECs used online reviews, increased meeting frequency and single/central REC. All SR-RECs had a member composition as required by the World Health Organisation ethics guidelines, while some NSR-RECs lacked non-affiliated and/or layperson members. SR-RECs reviewed more COVID-related product development protocols and indicated challenges in reviewing risk/benefit and vulnerability (0.010), informed consent form (0.002), and privacy and confidentiality (P = 0.020) than NSR-RECs. Conclusions Surveyed RECs had a general knowledge of REC operation and played a significant role in reviewing COVID-19-related product development protocols. Having active networks of RECs across regions to share updated information and resources could be one of the strategies to promote readiness for future public health emergencies.

show abstract

Section: The Ability Of Recs To Identify General Ethical Issues Invol...mentioning

confidence: 99%

The readiness of the Asian research ethics committees in responding to the COVID-19 pandemic: A multi-country survey

Karbwang,

Torres,

Navarro

et al. 2024

F1000Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most patients usually present with no to mild symptoms such as fever, upper respiratory tract symptoms, headache, fatigue, and loss of taste and smell without lower respiratory tract symptoms ( 1 ). The guidelines of COVID-19 treatment recommend conservative and symptomatic treatment for mild and uncomplicated diseases while antiviral therapy, corticosteroid, and other advanced treatments are recommended in moderate to severe infections or in patients with comorbidities at risk for disease progression ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial

Kanokkangsadal,

Mingmalairak,

Mukkasombat

et al. 2023

Research in Pharmaceutical Sciences

View full text Add to dashboard Cite

Background and purpose: Andrographis paniculata (Burm.f.) Nees has been recommended to relieve symptoms and decrease the severity of COVID-19. The clinical study aimed to investigate the efficacy and safety of A. paniculata ethanolic extract (APE). Experimental approach: The efficacy and safety of APE in asymptomatic or mildly symptomatic COVID-19 patients compared with placebo were investigated through a prospective, double-blind randomized control trial. Patients received APE containing 60 mg of andrographolide, three times a day for five days. WHO progression scale, COVID-19 symptoms, and global assessment evaluated the efficacy and adverse events, liver and renal functions were monitored for safety. Findings/Results: 165 patients completed the study (83 patients in the APE group and 82 patients in the placebo group). The highest WHO progression scale was 4 and COVID-19 symptoms were significantly relieved on the last day of intervention in both groups, with no significant difference between groups. APE significantly relieved headache symptoms on day 1 and olfactory loss symptoms on day 2 compared to placebo. The global assessment showed that 80.7% of patients had total recovery after 5-day treatment with APE. Mild diarrhea was the most common side effect with a high dose that resolved within a few days. No hepatic or renal toxicity was associated with treatment. Conclusion and implications: APE at 180 mg/day for 5 days did not reduce COVID-19 progression in asymptomatic or mildly afflicted COVID-19 patients, however, it shortened the symptoms of olfactory loss with no adverse effects over 5 days of use.

show abstract

Antivirals in Wastewaters and Receiving Waters: Analytical Methods and Occurrence Data

Dogruel,

Bilgin-Saritas,

Akbarniashahrivar

et al. 2024

Water and Wastewater Management

View full text Add to dashboard Cite

Perspective: repurposed Drugs for COVID-19

Cited by 7 publications

References 126 publications

The readiness of the Asian research ethics committees in responding to the COVID-19 pandemic: A multi-country survey

The readiness of the Asian research ethics committees in responding to the COVID-19 pandemic: A multi-country survey

Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial

Antivirals in Wastewaters and Receiving Waters: Analytical Methods and Occurrence Data

Contact Info

Product

Resources

About